This is read by an automated voice. Please report any issues or inconsistencies here. San Diego-based Avidity Biosciences Inc. agreed to be acquired by Novartis AG in a deal valued at $12 billion.
Closing expected in 1H2026 subject to completion of the separation of SpinCo from Avidity and other customary closing conditions "Avidity has expanded the possibilities of what RNA therapeutics can ...
Aligned with FDA on del-brax accelerated and full approval pathways for FSHD, reported positive topline data from Phase 1/2 FORTITUDE™ trial, and initiated global confirmatory Phase 3 study Planned ...
On track to deliver key regulatory updates for del-brax and topline data from dose escalation cohorts in the FORTITUDE™ trial in the second quarter Positive topline del-zota data further supports ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback